Compare Globus Medical Inc. Class A Common Stock (GMED) vs Texas Instruments Incorporated (TXN) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Texas Instruments (TXN) trades at $287.85, up 2.17% with strong technical support at $278 and resistance at $288. The company shows improving fundamentals with Q2 2026 EPS beating expectations at $2.14 versus $1.94, and revenue growth accelerating from $17.7B in 2025 to projected $19.5B in 2026. Operating cash flow strengthened to $7.15B in 2025, supporting consistent dividend payments.

TXN presents a compelling investment case with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key risks include premium valuation (P/E 43.75) and rising debt-to-asset ratio (40.61% in 2025). The data center segment's doubling sales and AI-driven semiconductor demand provide growth catalysts, though competitive pressures and cyclical industry dynamics warrant monitoring.